Brodalumab Is Associated with High Rates of Complete Clearance and Quality of Life Improvement : A Subgroup Analysis of Patients with Psoriasis and Concomitant Psoriatic Arthritis
Kokolakis, Georgios (Charité - Universitätsmedizin Berlin)
Vadstrup, Kasper (LEO Pharma A/S (Dinamarca))
Hansen, Jes B. (LEO Pharma A/S (Dinamarca))
Carrascosa, José Manuel (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Universitat Autònoma de Barcelona

Date:	2021
Abstract:	Psoriatic arthritis (PsA) is a chronic inflammatory disease associated with psoriasis that significantly impairs physical function and quality of life (QoL). Prompt therapeutic intervention is crucial for limiting PsA progression and preventing disability. The aim of this study was to compare the efficacy of brodalumab versus ustekin­umab and the impact on QoL in patients with moderate-to-severe plaque psoriasis, by concomitant PsA status. This post hoc analysis of pooled data from the phase 3 AMAGINE-2 and −3 trials evaluated complete skin clearance (100% improvement of Psoriasis Area and Severity Index [PASI 100]), improvement in symptom severity (Psoriasis Symptom Inventory [PSI] response), and QoL (Dermatology Life Quality Index [DLQI] score of 0/1) by concomitant PsA status. A competing risk model assessed cumulative incidence over 52 weeks with outcomes of PASI 100 or inadequate response. This analysis included 929 patients with moderate-to-severe psoriasis. Concomitant PsA was present in 79/339 (23%) and 110/590 (19%) patients receiving brodalumab 210 mg and ustekinumab, respectively. At Week 52, odds ratios (ORs) (95% confidence intervals [CIs]) for complete clearance with brodalumab versus ustekin­umab were 3. 15 (1. 52-6. 55, p = 0. 0015) in patients with concomitant PsA and 3. 05 (2. 19-4. 26, p < 0. 0001) in patients without concomitant PsA. Corresponding Week 52 ORs (95% CIs) for DLQI 0/1 with brodalumab versus ustekinumab were 2. 05 (1. 07-3. 90, p = 0. 0277) and 1. 83 (1. 32-2. 53, p = 0. 0002); Week 52 ORs (95% CIs) for PSI ≤8 with brodalumab versus ustekinumab were 3. 42 (1. 43-8. 18, p = 0. 0036) and 1. 40 (1. 01-1. 95, p = 0. 0434). The 52-week cumulative incidence of patients achieving PASI 100 was significantly higher for brodalumab versus ustekinumab in patients with concomitant PsA (p = 0. 0001) and in those without concomitant PsA (p < 0. 0001). Treatment with brodalumab rapidly results in high levels of complete and sustained skin clearance and greater cumulative treatment benefit in patients with moderate-to-severe psoriasis versus ustekinumab, regardless of concomitant PsA status.
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	Brodalumab ; Psoriasis ; Psoriatic arthritis ; QoL ; Ustekinumab
Published in:	Dermatology (Basel, Switzerland), Vol. 238 (november 2021) , p. 620-629, ISSN 1421-9832

DOI: 10.1159/000520290
PMID: 34823247

16 p, 827.8 KB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP)
Articles > Research articles
Articles > Published articles